Skip to main content
. Author manuscript; available in PMC: 2020 Jan 15.
Published in final edited form as: Clin Cancer Res. 2018 Sep 10;25(2):663–673. doi: 10.1158/1078-0432.CCR-18-0926

Figure 5. Combination therapy with STAT3 inhibitor restores sensitivity to MET inhibitors in resistant GBM cells.

Figure 5.

U373 wild type (WT), crizotinib-resistant (CR) & Onartuzumab-resistant (OR) cells were pretreated with a STAT3 inhibitor (25 μM) for 2 hr then subsequently treated with either A). crizotinib (100 nM) or B). Onartuzumab (Onart) (300 nM) for 48 hr. Cell death was assessed via trypan blue. U373 cells were pretreated with STAT3 inhibitor (25 μM) for 2 hrs then subsequently treated with either C). crizotinib (100 nM) or D). Onart (300 nM) for 48 hr. Cell proliferation was assessed by cell counting over a period of 5 days and growth curves were established. *, P < 0.05.